According to filings with the U.S. Securities and Exchange Commission, GRIP Molecular Technologies is raising $9,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Edward Gillen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About GRIP Molecular Technologies
GRIP Molecular is developing a novel, patent-protected, chip-based electronic biosensor that will provide lab-grade diagnostic results in minutes using a mobile device at the point of need. Unlike existing diagnostic technologies, it has the capability to simultaneously detect various diseases and characterize their state of infection (infectious to immune) with a single test. GRIP uses a combination of novel nanomaterials and patented 3D printing to deliver accurate results in minutes without the burden of complex chemistry. The appearance of COVID-19 as a global health threat has increased the urgency to transform diagnostics, which the GRIP team was well into even before this threat emerged. The ability to quickly, easily and cost-effectively test for active infection and immunity at the point of need has become the new baseline for what we should expect for early detection of all kinds of disease, but particularly when fighting a pandemic level enemy. GRIP is committed to confirm the science and commercialize a new approach with a number of specific panels/products that address our most challenging diseases and chronic conditions.

To learn more about GRIP Molecular Technologies, visit http://www.gripmolecular.com/

Contact:
Edward Gillen, Chief Executive Officer
866-437-4752
https://www.linkedin.com/in/edward-gillen

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.